Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.60 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30413950 | 1.00 | KDR (0.67) | KDRKMT2AMAPTMEN1HTT | |
| SCHEMBL12443228 | 0.89 | MAPT (0.74) | KDRKMT2AMAPTMEN1HTT | |
| SCHEMBL4556067 | 0.88 | KDR (0.75) | KDRKMT2AMEN1HTTRAB9A | |
| SCHEMBL3672232 | 0.86 | NTRK1 (0.70) | KDRKMT2AMAPTMEN1HTT | |
| SCHEMBL5597699 | 0.85 | KMT2A (0.90) | KDRKMT2AMAPTMEN1HTT | |
| SCHEMBL30101230 | 0.85 | KMT2A (0.90) | KDRKMT2AMAPTMEN1HTT | |
| SCHEMBL3692790 | 0.84 | KDR (0.73) | KDRKMT2AMAPTMEN1HTT | |
| SCHEMBL14601707 | 0.84 | KMT2A (0.77) | KDRKMT2AMAPTMEN1HTT | |
| SCHEMBL5504593 | 0.84 | MAPT (0.66) | KMT2AMAPTMEN1HTTRAB9A | |
| SCHEMBL13202441 | 0.84 | MAPT (0.70) | KMT2AMAPTMEN1HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4405644-A | BICARBOCYCLIC ARYL UREA OR THIOUREA COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 1983-09-20 | — | — | US | claimed |
| US-10420781-B2 | Thyroid hormone receptor agonist and use thereof | METABASIS THERAPEUTICS INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20180344752-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | METABASIS THERAPEUTICS INC. | 2018-12-06 | — | — | US | disclosed |
| US-20170319604-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | METABASIS THERAPEUTICS, INC. | 2017-11-09 | — | — | US | disclosed |
| US-8262634-B1 | Absorbent article having barrier sheet against the migration of the skin care composition | THE PROCTER & GAMBLE COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| US-20120046364-A1 | Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use | METABASIS THERAPEUTICS, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2011038207-A1 | PHOSPHORUS-CONTAINING THYROID HORMONE RECEPTOR AGONISTS AND METHODS OF USE | METABASIS THERAPEUTICS, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| US-7829552-B2 | Phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20100081634-A1 | Novel Phosphorus-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20090232879-A1 | Thyromimetics for the Treatment of Fatty Liver Diseases | METABASIS THERAPEUTICS, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| US-20060029567-A1 | Material for odor control | BKI HOLDING CORPORATION (US) | 2006-02-09 | — | — | US | disclosed |
| US-20050075377-A1 | PPAR compounds | PFIZER INC | 2005-04-07 | — | — | US | disclosed |
| US-20040248934-A1 | Tetrahydroisoquinoline derivatives as PPAR-alpha activators | PFIZER INC. | 2004-12-09 | — | — | US | disclosed |
| US-6703536-B2 | ENZYME INHIBITOR IS TRANSFERRED TO SKIN WITH SKIN CARE COMPOSITION AND IS AVAILABLE AT SKIN/URINE AND SKIN/FECES INTERFACES TO INHIBIT ENZYMATIC ACTIVITY ON SKIN AND TO REDUCE OR PREVENT OCCURRENCE OF INFLAMMATION | THE PROCTER & GAMBLE COMPANY | 2004-03-09 | — | — | US | disclosed |
| US-6699904-B2 | PEROXISOME PROLIFERATOR ACTIVATOR RECEPTOR (PPAR) AGONISTS; ATHEROSCLEROSIS AND CARDIOVASCULAR DISORDERS; FOR EXAMPLE, 3-(4-(2-(3-(2,4-DIMETHOXY-PHENYL)-1-HEPTYL-UREIDO)-ETHYL)-PHENYL)-2-ETHOXY -PROPIONIC ACID | PFIZER INC. | 2004-03-02 | — | — | US | disclosed |
| US-20030139711-A1 | Disposable absorbent article having a skin care composition containing an enzyme inhibitor | THE PROCTER & GAMBLE COMPANY | 2003-07-24 | — | — | US | disclosed |
| US-20020165282-A1 | Peroxisome proliferator activator receptor (PPAR) agonists; atherosclerosis and cardiovascular disorders; for example, 3-(4-(2-(3-(2,4-dimethoxy-phenyl)-1-heptyl-ureido)-ethyl)-phenyl)-2-ethoxy -propionic acid | HAYWARD CHERYL M (US) | 2002-11-07 | — | — | US | disclosed |
| EP-1061962-A1 | DISPOSABLE ABSORBENT ARTICLE HAVING A SKIN CARE COMPOSITION CONTAINING AN ENZYME INHIBITOR | THE PROCTER & GAMBLE COMPANY (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999045973-A1 | DISPOSABLE ABSORBENT ARTICLE HAVING A SKIN CARE COMPOSITION CONTAINING AN ENZYME INHIBITOR | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-16 | — | — | WO | disclosed |
| US-5643874-A | ANTIOBESITY AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1997-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10420781-B2 | Thyroid hormone receptor agonist and use thereof | THRB, THRA, TSHR | KDR 824/4885KMT2A 2948/4885MAPT 1781/4885 |
| US-20020165282-A1 | Peroxisome proliferator activator receptor (PPAR) agonists; atherosclerosis and cardiovascular disorders; for example, 3-(4-(2-(3-(2,4-dimethoxy-phenyl)-1-heptyl-ureido)-ethyl)-phenyl)-2-ethoxy -propionic acid | PPARA, PPARG, PPARD | KDR 658/4885KMT2A 3747/4885MAPT 2892/4885 |
| US-20100081634-A1 | Novel Phosphorus-Containing Thyromimetics | PYGL, THRA, THOP1 | KDR 3982/4885KMT2A 4004/4885MAPT 3512/4885 |
| US-20120046364-A1 | Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use | THRB, TSHR, THRA | KDR 3097/4885KMT2A 3382/4885MAPT 4733/4885 |
| US-20180344752-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | THRB, THRA, TSHR | KDR 824/4885KMT2A 2948/4885MAPT 1781/4885 |
| US-20170319604-A1 | THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF | THRB, THRA, TSHR | KDR 824/4885KMT2A 2948/4885MAPT 1781/4885 |
| US-20090232879-A1 | Thyromimetics for the Treatment of Fatty Liver Diseases | TSHR, THRA, FABP1 | KDR 2841/4885KMT2A 2797/4885MAPT 4318/4885 |
| US-20050075377-A1 | PPAR compounds | PPARA, PPARG, PPARD | KDR 910/4885KMT2A 3388/4885MAPT 2750/4885 |
| US-20040248934-A1 | Tetrahydroisoquinoline derivatives as PPAR-alpha activators | PPARA, PPARG, PPARD | KDR 1226/4885KMT2A 2154/4885MAPT 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.